Chief Executive Officer
John Boyce is an energetic leader and serial entrepreneur who has successfully raised over $100MM in funding from venture capital and private investors. Most recently, Mr. Boyce was the President and Chief Executive Officer (CEO) of GnuBIO, Inc, a desktop DNA sequencing company that he co-founded in January 2011. Mr. Boyce raised a total of $18MM over two rounds of investor funding and based on the clinical strategy and product roll out initiative that he put in place, GnuBIO was acquired by Bio-Rad in April 2014 for a deal valued at $110MM. Prior to GnuBIO, Mr. Boyce started and sold Affomix (a digital proteomics company) to Illumina resulting in a significant return on investment for investors and shareholders within two years. Through the course of his career, he served in key positions in numerous life sciences companies to drive them either towards an acquisition or an IPO. Mr. Boyce also conceived, founded, and ran the Consumer Genetics Conference, which was acquired by Cambridge Healthtech Institute in 2012. In 2013, Mr. Boyce was awarded the honor as one of the top 15 technology luminaries in Massachusetts by the Boston Business Journal and Mass High Technology. In 2014, Mr. Boyce was made a Fellow at Harvard University and teaches "Innovation in Science and Engineering" (ES-139).
Thomas McLain, MBA, CPA
Chief Operating Officer
Tom McLain has over 20 years of experience and a proven track record evolving diagnostics and biopharmaceutical companies from early-stage ventures to successful commercial organizations. Most recently as Chief Executive Officer (CEO) of Vermillion, a medical diagnostics company focused on women’s health, Mr. McLain led a strategic transformation that resulted in a fivefold increase in the company’s market capitalization. Prior to joining Vermillion, Mr. McLain was the CEO of Claro Scientific, a diagnostics start-up with a novel optics-based platform technology. He also previously served as chairman, CEO and president of Nabi Biopharmaceuticals where he led the evolution of a plasma supply-based business into a fully integrated biopharmaceutical company. Over his career, Mr. McLain has raised over $1 billion in new capital and structured numerous successful commercial alliances, joint ventures and research collaborations. Mr. McLain also served as a director, chairman of the health, safety, environment and security committee and member of the audit and finance committees at Eastman Chemical Company and as chairman of the board of Nabi Biopharmaceuticals. He has been active in the life sciences industry, serving as Chairman of the Board of BioFlorida for seven years and as a board member of the Biotechnology Industry Organization and the Southeastern Medical Device Association. Mr. McLain earned his BA at the College of the Holy Cross, and his MBA from the University of Rochester.
Johan Skog, PhD
Chief Scientific Officer and Founding Scientist
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.
William J. Kelly, CPA
Chief Financial Officer
William Kelly has over 20 years of financial management experience, including senior roles at emerging, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer (CFO) of RepliGen Corporation and Corporate Controller of Haemonetics. While at RepliGen Corporation, Mr. Kelly helped lead the company through a transformation from a research entity valued at $100M to a commercial enterprise worth over $600M. He began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds a BA in psychology from the College of the Holy Cross and an MS/MBA from Northeastern University.
Mikkel Noerholm, PhD
Vice President Product Development
Mikkel Noerholm heads European operations for Exosome Diagnostics from the company’s site in Munich, Germany. He previously served as Research Scholar at Massachusetts General Hospital/Harvard Medical School where he worked closely with Dr. Skog to develop exosome technology. Dr. Noerholm’s previous corporate experience includes being instrumental in establishing Exiqon, Inc., where he held the role of Director of Technical Support. He also previously served as R&D Project Manager at Exiqon A/S in Denmark, where he led the development of what is now that company’s miRCURY LNA Arrays. Dr. Noerholm has a PhD in micro- and biotechnology from the Technical University of Denmark and an MBA from Babson College.
Vice President Regulatory Affairs and Quality
Raaj Venkatesan brings more than 10 years of experience in regulatory affairs, regulatory compliance and quality engineering in the medical device and In Vitro Diagnostics industry. Prior to joining Exosome Diagnostics, Raaj served as Director of Regulatory Affairs and Quality at Bio-Rad Laboratories, where he was responsible for leading the regulatory affairs and compliance for a next-generation sequencing in vitro diagnostic product. Prior to that, Raaj held various regulatory affairs and quality engineering positions at Bruker Daltonics, OmniGuide Surgical, Becton Dickinson (BD) Diabetes Care and Second Sight Medical Products. Raaj is Regulatory Affairs Certified (RAC-US, RAC-EU) by the Regulatory Affairs Professionals Society (RAPS) and is also an ASQ Certified Manager of Quality, Reliability Engineer, Quality Auditor, Biomedical Auditor and Quality Engineer. He earned his Master’s Degrees in Biomedical Engineering, Electrical Engineering and Medical Device and Diagnostic Engineering from the University of Southern California and Bachelor’s Degree in Electronics and Instrumentation Engineering from Bharathidasan University in India.